Get the Stockscreener App
3.41
2.01%
-0.07
After Hours:
3.41
Editas Medicine Inc stock is traded at $3.41, with a volume of 1.55M.
It is down -2.01% in the last 24 hours and down -8.82% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$3.48
Open:
$3.48
24h Volume:
1.55M
Relative Volume:
0.87
Market Cap:
$280.83M
Revenue:
$78.12M
Net Income/Loss:
$-153.22M
P/E Ratio:
-1.152
EPS:
-2.96
Net Cash Flow:
$-136.90M
1W Performance:
-6.83%
1M Performance:
-8.82%
6M Performance:
-54.04%
1Y Performance:
-56.28%
1-Day Range:
$3.39
$3.615
1-Week Range:
$3.37
$3.70
52-Week Range:
$3.37
$11.69
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Wall Street SWOT: Editas Medicine stock faces challenges in competitive gene editing market - Investing.com
Wall Street SWOT: Editas Medicine stock faces challenges in competitive gene editing market - Investing.com India
CRISPR and CRISPR-Associated (Cas) Genes Market 2024 Business Standards and Competition Landscape 2032 – Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics – Cauverynews - Cauverynews
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth? - Simply Wall St
Editas Medicine stock hits 52-week low at $3.4 amid challenges - Investing.com Australia
Editas Medicine stock hits 52-week low at $3.4 amid challenges By Investing.com - Investing.com South Africa
Editas Medicine stock hits 52-week low at $3.4 amid challenges - Investing.com
Editas Medicine stock hits 52-week low at $3.4 amid challenges - Investing.com India
Editas Medicine stock hits 52-week low at $3.4 amid challenges - Investing.com UK
Editas Medicine: A Risk/Reward Worth Considering (NASDAQ:EDIT) - Seeking Alpha
Integral Health Asset Management LLC Has $3.15 Million Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Rating Reaffirmed by Royal Bank of Canada - MarketBeat
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) PT at $11.22 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Up 6.6% in August - MarketBeat
Where Editas Medicine Stands With Analysts - Benzinga
Where Editas Medicine Stands With Analysts - Nasdaq
Los Angeles Capital Management LLC Reduces Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Sickle Cell Disease Treatment Market 2024 Consumer Needs – Agios Pharmaceuticals, Bristol-Myers Squibb, CRISPR Therapeutics, Editas Medicine – Cauverynews - Cauverynews
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% - GlobeNewswire Inc.
Allspring Global Investments Holdings LLC Makes New Investment in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine CEO sells shares worth over $5,000 - Investing.com India
Editas Medicine executive sells over $1,700 in stock - Investing.com India
Editas Medicine executive sells over $1,700 in stock - Investing.com
Editas Medicine CEO sells shares worth over $5,000 By Investing.com - Investing.com Canada
Editas Medicine CEO sells shares worth over $5,000 By Investing.com - Investing.com UK
Editas Medicine stock hits 52-week low at $3.4 amid downturn - Investing.com
Editas Medicine stock hits 52-week low at $3.4 amid downturn - Investing.com Canada
Editas Medicine stock hits 52-week low at $3.4 amid downturn - Investing.com UK
Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
BofA upgrades Editas to buy, cites reni-cel progress - MSN
Editas Medicine (EDIT) Advancing Gene Editing Amid Struggles - Stocks Telegraph
Raymond James & Associates Raises Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Raymond James & Associates Buys 174,993 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Top 5 CRISPR Companies To Invest In (September 2024) - Securities.io
Zacks Research Comments on Editas Medicine, Inc.'s Q3 2024 Earnings (NASDAQ:EDIT) - MarketBeat
Q3 2024 EPS Estimates for Editas Medicine, Inc. (NASDAQ:EDIT) Reduced by Analyst - Defense World
Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology - GlobeNewswire Inc.
Who are the leading innovators in CRISPR nucleases for the pharmaceutical industry? - Pharmaceutical Technology
Editas Medicine stock hits 52-week low at $3.71 By Investing.com - Investing.com Canada
Editas Medicine stock hits 52-week low at $3.71 - Investing.com India
Editas Medicine stock hits 52-week low at $3.71 - Investing.com
Editas Medicine stock hits 52-week low at $3.71 By Investing.com - Investing.com Australia
Editas Medicine stock hits 52-week low at $3.71 By Investing.com - Investing.com UK
Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences - StockTitan
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet - Simply Wall St
Page 71 – Impact Investing - Equities News
Hennion & Walsh Asset Management Inc. Acquires New Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Hennion & Walsh Asset Management Inc. Invests $786,000 in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
California State Teachers Retirement System Cuts Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):